- Ultragenyx Pharmaceutical ( NASDAQ: RARE ) on Friday said it sees total product revenue of $425M-$450M in 2023 with the vast majority of it -- $325M-$340M -- coming from Crysvita (burosumab).
- The rare diseases focused biotech also sees preliminary 2022 product revenues of $352M-$356M.
- The consensus revenue estimate for 2022 is $360.21M. For 2023, it is $444.66M.
- Ultragenyx ( RARE ) said it ended 2022 with a cash balance of ~$900M.
- Crysvita is an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia.
- Read why Seeking Alpha contributor Avisol Capital Partners rates Ultragenyx ( RARE ) a hold.
For further details see:
Ultragenyx sees 2023 product revenue of $425M-$450M